AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

NBIX · NASDAQ · Biotechnology

Neurocrine Biosciences (NBIX)

Develops and commercializes neuroscience and rare-disease medicines led by INGREZZA.

$144.04

After hours+1.80 (+1.27%)

At close$142.24(−1.19%)

Integrated Wealth Concepts LLC Sells 5,703 Shares of Neurocrine Biosciences, Inc. $NBIX
Defense WorldSep 17
Corient Private Wealth LP Buys 9,645 Shares of Neurocrine Biosciences, Inc. $NBIX
Defense WorldSep 17
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking AlphaSep 15
Engineers Gate Manager LP Increases Holdings in Neurocrine Biosciences, Inc. $NBIX
Defense WorldSep 14
Amundi Has $37.16 Million Position in Neurocrine Biosciences, Inc. $NBIX
Defense WorldSep 11Ownership
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Seeking AlphaSep 10Earnings
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking AlphaSep 9Earnings
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Continuum Advisory LLC
Defense WorldSep 8Ownership
B. Metzler seel. Sohn & Co. AG Acquires New Shares in Neurocrine Biosciences, Inc. $NBIX
Defense WorldAug 24Ownership
Allworth Financial LP Invests $2.50 Million in Neurocrine Biosciences, Inc. $NBIX
Defense WorldAug 22Ownership
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
Zacks Investment ResearchAug 20Earnings
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Zacks Investment ResearchAug 20Earnings
BlackRock Inc. Takes $2.31 Billion Position in Neurocrine Biosciences, Inc. $NBIX
Defense WorldAug 20Ownership
14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V.
Defense WorldAug 16
What's Going On With Neurocrine Biosciences Stock On Wednesday?
BenzingaAug 12
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
PRNewsWireAug 12
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug
ReutersAug 12
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers
Defense WorldAug 8
Glenmede Trust Co. NA Has $10.35 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX
Defense WorldAug 3
NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth
Zacks Investment ResearchJul 31